# A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

> **NCT00216632** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 99 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00216632
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2012-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216632, "A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00216632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*